BMJ OncologyPub Date : 2024-02-01DOI: 10.1136/bmjonc-2023-000171
Maarten Cuypers, Deborah Cairns, Kathryn A. Robb
{"title":"Identifying the deficits in cancer care for people with intellectual disabilities","authors":"Maarten Cuypers, Deborah Cairns, Kathryn A. Robb","doi":"10.1136/bmjonc-2023-000171","DOIUrl":"https://doi.org/10.1136/bmjonc-2023-000171","url":null,"abstract":"","PeriodicalId":505335,"journal":{"name":"BMJ Oncology","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139828811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMJ OncologyPub Date : 2024-01-01DOI: 10.1136/bmjonc-2023-000073
B. Budnik, Hossein Amirkhani, M. Forouzanfar, A. Afshin
{"title":"Novel proteomics-based plasma test for early detection of multiple cancers in the general population","authors":"B. Budnik, Hossein Amirkhani, M. Forouzanfar, A. Afshin","doi":"10.1136/bmjonc-2023-000073","DOIUrl":"https://doi.org/10.1136/bmjonc-2023-000073","url":null,"abstract":"Early detection of cancer is crucial for reducing the global burden of cancer, but effective screening tests for many cancers do not exist. This study aimed to develop a novel proteome-based multi-cancer screening test that can detect early-stage cancers with high accuracy.We collected plasma samples from 440 individuals, healthy and diagnosed with 18 early-stage solid tumours. Using proximity extension assay, we measured more than 3000 high-abundance and low-abundance proteins in each sample. Then, using a multi-step statistical approach, we identified a limited set of sex-specific proteins that could detect early-stage cancers and their tissue of origin with high accuracy.Our sex-specific cancer detection panels consisting of 10 proteins showed high accuracy for both males (area under the curve (AUC): 0.98, 95% CI 0.96, 1) and females (AUC: 0.983, 95% CI 0.95, 1.00). At stage I and at the specificity of 99%, our panels were able to identify 93% (95% CI 79%, 100%) of cancers among males and 84% (95% CI 68%, 100%) of cancers among females. Our sex-specific localisation panels consisted of 150 proteins and were able to identify the tissue of origin of most cancers in more than 80% of cases. The analysis of the plasma concentrations of proteins selected showed that almost all the proteins were in the low-concentration part of the human plasma proteome.The proteome-based screening test showed promising performance compared with other technologies and could be a starting point for developing a new generation of screening tests for the early detection of cancer.","PeriodicalId":505335,"journal":{"name":"BMJ Oncology","volume":"19 14","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139455905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMJ OncologyPub Date : 2024-01-01DOI: 10.1136/bmjonc-2023-000184
Holli A. Loomans-Kropp
{"title":"Multi-cancer early detection tests: a strategy for improvement","authors":"Holli A. Loomans-Kropp","doi":"10.1136/bmjonc-2023-000184","DOIUrl":"https://doi.org/10.1136/bmjonc-2023-000184","url":null,"abstract":"","PeriodicalId":505335,"journal":{"name":"BMJ Oncology","volume":"40 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139454884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMJ OncologyPub Date : 2024-01-01DOI: 10.1136/bmjonc-2023-000287
Daniel A Goldstein, Leonard B Saltz, Gregory R. Pond, I. F. Tannock
{"title":"Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending","authors":"Daniel A Goldstein, Leonard B Saltz, Gregory R. Pond, I. F. Tannock","doi":"10.1136/bmjonc-2023-000287","DOIUrl":"https://doi.org/10.1136/bmjonc-2023-000287","url":null,"abstract":"In the field of general medicine, class effects, or therapeutic interchangeability, have been declared for several families of drugs including statins, calcium channel blockers and ACE inhibitors. The existence of such class effects enables healthcare payers to negotiate for substantially lower drug prices, thereby reducing financial toxicity, both at an individual and societal levels. Until now, the existence of class effects in oncology has been considered rare. Here, we review evidence from clinical trials that supports the existence of class effects for several types of anticancer drugs. These class effects in oncology should be exploited to reduce healthcare costs.","PeriodicalId":505335,"journal":{"name":"BMJ Oncology","volume":"64 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140525126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
